Recombinant DT3C Protein: Structural Features, Production Workflows and Multi‑Field Basic‑Research Applications

Molecular Architecture and Recombinant Expression System Selection for DT3C

Recombinant DT3C represents an engineered fusion protein assembled from three functional modular segments: D‑domain for receptor docking, T‑domain responsible for membrane translocation, and 3C protease functional unit. This polypeptide totals approximately 320 amino‑acid residues with a nominal molecular weight of 35 kDa. Each discrete domain undertakes defined tasks supporting target‑cell recognition, membrane penetration and localized proteolytic cleavage events within cellular experimental systems.

Multiple heterologous expression platforms can generate recombinant DT3C protein for laboratory usage. Escherichia coli constitutes the most widely‑adopted host, delivering yields ranging 50‑100 mg soluble protein per litre of culture medium after codon optimization and induction‑condition tuning. This bacterial system brings operational convenience and relatively low associated experimental costs.

Mammalian expression hosts such as HEK293 or CHO cell lines prove suitable when authentic eukaryotic post‑translational modifications are required, though typical output drops to 5‑20 mg per litre culture volume. Baculovirus‑driven insect‑cell systems sit as an intermediate alternative, achieving 20‑50 mg/L yields while favouring native‑like protein folding patterns. Researchers must match host‑system selection against project‑specific functional‑assay requirements.

Purification Pipeline and Multi‑Dimensional Quality‑Control Specifications

Because the embedded 3C protease domain may degrade host‑derived proteins during sample processing, cell lysate material must be supplemented with protease‑inhibitor cocktails and maintained under low‑temperature conditions immediately after cell harvesting. Standard multi‑step purification workflows start with Ni‑based affinity chromatography targeting His‑tagged DT3C molecules, routinely reaching roughly 80 % purity after this initial capture step.

Subsequent ion‑exchange chromatography using Q Sepharose HP resin removes residual host‑cell proteins and contaminating nucleic‑acid species. Size‑exclusion chromatography with Superdex 75 or Superdex 200 media further eliminates protein aggregates, bringing final product purity above 95 % for downstream cell‑based assays.

Comprehensive quality‑control panels underpin experimental reproducibility. SDS‑PAGE and western‑blot techniques verify protein identity and bulk purity; HPLC quantifies monomer‑to‑aggregate ratios. Mass‑spectrometry workflows confirm molecular mass and detect oxidative or degradative modification forms. Proteolytic activity gets measured with fluorogenic peptide substrate Dabcyl‑FRLKMAE‑Edans, requiring specific activity values no less than 5000 U/mg. Endotoxin content shall stay below 1 EU/μg for cell‑culture and animal‑model experimental workflows. Stability testing shows DT3C remains functional for over 12 months stored at −80 °C in pH 7.4 buffer, retaining activity for 2‑3 weeks under 4 °C; repeated freeze‑thaw cycles exceeding three times produce measurable loss of enzymatic potency.

Intracellular Mechanism and Dose‑Dependent Cellular Biological Responses

DT3C executes target‑cell action through a sequential multi‑molecular cascade. Its N‑terminal D‑domain binds cell‑surface receptors such as CD46 or CD55 with nanomolar‑range affinity (Kd ≈ 10‑50 nM). After receptor engagement, the whole protein complex becomes internalised through endocytic vesicle compartments. Acidified endosomal microenvironments trigger conformational rearrangement within the T‑translocation domain, facilitating polypeptide translocation across vesicle membranes toward cytoplasmic compartments.

Once liberated into cytosol, the 3C protease unit becomes catalytically activated, cleaving polypeptide substrates carrying consensus LEVLFQ↓GP recognition motifs. Such proteolytic processing can perturb key cell‑cycle‑regulatory proteins including Rb and p21 and drive either cell‑cycle arrest or apoptotic cell death phenotypes.

DT3C generates concentration‑dependent cellular readouts in tissue‑culture experiments. Concentrations of 1‑10 nM predominantly induce G1‑phase cell‑cycle arrest linked to proteolytic processing of cell‑cycle‑control molecules. Intermediate doses between 10‑100 nM trigger obvious apoptotic markers such as mitochondrial‑membrane‑potential dissipation, caspase‑3 activation and DNA fragmentation events. Concentrations above 100 nM may elicit non‑apoptotic necrotic‑type cell demise. Selected tumour‑cell lines display heightened DT3C susceptibility with IC50 values 10‑100‑fold lower compared to non‑transformed cellular counterparts. Transcriptomic profiling demonstrates approximately 1200 significantly altered gene transcripts after six‑hour DT3C exposure, covering apoptosis‑related, inflammatory‑response and metabolic‑reprogramming signalling networks.

Pre‑Clinical Basic‑Research Application Landscapes for Recombinant DT3C Protein

Within on‑cology‑oriented laboratory investigations, local DT3C administration suppresses tumour‑growth kinetics across mouse xenograft models for melanoma, breast carcinoma and glioma, recording tumour‑inhibition rates spanning 50‑80 %. Compared with conventional small‑molecule chemotherapy reagents, DT3C‑treated animal cohorts exhibit milder body‑weight loss and reduced haematological‑system‑related toxic phenotypes. Protein‑engineering approaches swap out the native D‑domain module to re‑target DT3C toward tumour‑associated antigens such as EGFR or HER2, refining selectivity for malignant‑cell populations. Combination setups pairing DT3C with immune‑checkpoint‑modulating antibodies produce synergistic anti‑tumour effects via immunogenic‑cell‑death induction.

Antiviral‑focused in‑vitro assays deploy DT3C protease activity to cleave replication‑critical proteins derived from multiple RNA‑virus families, including HCV NS3/4A and SARS‑CoV‑2‑associated 3CLpro components. Appropriate DT3C treatment can depress viral titres by 2‑3 orders of magnitude within infected cell‑culture systems. Derived small‑molecule inhibitor candidates targeting the 3C‑protease catalytic pocket also undergo iterative pre‑clinical evaluation in antiviral‑drug‑discovery pipelines.

DT3C also delivers utility for tissue‑engineering and regenerative‑medicine basic‑research workflows. Compared with harsh trypsin or Triton‑X‑100 treatments, DT3C‑assisted decellularization better preserves native collagen architecture and embedded growth‑factor reservoirs inside cardiac tissue scaffolds. Implanted DT3C‑processed constructs demonstrate 2‑3‑fold enhanced vascularization responses in animal‑model implantation assays. Modified fibrin biomaterial scaffolds incorporating DT3C support guided axonal outgrowth for neural‑regeneration experimental setups.

Recombinant DT3C Research‑Grade Protein from ANT BIO PTE. LTD.

ANT BIO PTE. LTD. supplies DT3C (Diphtheria toxin & spg 3C domain) Protein, Corynephage beta (catalog UA070063). This unconjugated recombinant protein is expressed in E. coli expression systems and has completed multi‑parameter quality‑control validation covering purity, enzymatic‑activity and endotoxin testing. This reagent supports oncology mechanism exploration, antiviral molecule screening and tissue‑decellularization‑related basic‑science laboratory projects.

Related Product Portfolio

Note: All listed products are intended exclusively for basic laboratory research use and shall not be applied for diagnostic or therapeutic purposes.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANTBIO, we are committed to advancing life science research through high‑quality, reliable reagents and comprehensive solutions. Our specialized sub‑brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer‑centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.

Disclaimer
This article was partially created with the assistance of artificial intelligence. If any content involves copyright or intellectual property issues, please inform us, and we promise to verify and remove it immediately.